Suppressed Paxil Suicide Data Released
Click here to access full story and data

This web site, combined with its public protests and other efforts, represent one of the few times in history a group of concerned United States citizens have come together in a high profile manner to warn the public about a dangerous and defective drug, and to protest the egregious conduct of its manufacturer and distributor — GlaxoSmithKline.

Our goal is to shine an unblinking spotlight on GlaxoSmithKline's unconscionable marketing and distribution of its drug sold in the United States as"Paxil", in the United Kingdom as "Seroxat" and in Australia as "Aropax". GSK further markets the drug under many other trade names throughout the world.

But Paxil is just "surface scum," if you will, covering a vast GlaxoSmithKline pharmaceutical cesspool. Hidden behind a “finely wrought fence” of top level executive deception is a corporate sewer pipe spewing dozens of dangerous and defective drugs into the marketplace; toxic drugs that:

  • have oftentimes emerged through sham clinical trials;
  • are frequently of dubious, or nonexistent, efficacy;
  • are typically approved after limited reviews by inept, lax or compromised drug regulatory agencies.
  • The result? A monstrous public health hazard wherein hundreds of thousands of people the world over have been seriously harmed — many killed — by GlaxoSmithKline's emporium of purportedly "safe and effective" drugs.

    Speaking of pipelines: What GSK does not have — even though the company's CEO Jean-Pierre Garnier regularly claims it — is a gleaming pipeline practically "bursting at the seams" with new “blockbuster” drugs.

    Far from it.

    In December 2003, Mr. Garnier trumpeted a product pipeline of 147 drugs or new chemical compounds to be tested. Now, two years later, Glaxo's most highly publicized late-stage drugs are terminally behind schedule or, in later critical trials — failures. Still others are on the verge of being beaten to the market by competitors. Little wonder Bear Stearns put an underperform rating on Glaxo's stock in June 2005, saying its analysis had identified a "high level of risk-taking for compounds in advanced development."

    If Mr. Garnier is going to be — as he crowed in April 2004 — "a hero in two or three years," then according to his own calendar he has (as of February 2006) only 2 to 14 months remaining to make good on that promise.

    The "Countdown to J.P. Garnier Hero Day" Timer

    Between now and Mr. Garnier’s deluded "hero's day," he must contend with:

  • Exposure of his "starring role" in the Paxil fraud, coupled with a long delayed but (we hope) inevitable trial; a trial in which his presence will be "mandatory";
  • GSK’s loss of several blockbuster drugs going off patent and thereafter losing huge chunks of market share to cheaper generics;
  • A raft of FDA "Black Box" or enhanced warnings being slapped on some of Glaxo's best-selling drugs (Advair, most recently);
  • Michael Moore's "Big Pharma" movie (scheduled for release in 2006.) Word is Glaxo will garner (Garnier?) star billing in Moore's movie, and if that's the case then investors will invariably see GSK's stock value "Mercked" (i.e. annihilated) by a panicked market.
  • A ... hero? Garnier is, if anything, a delusional megalomaniac who is going to be finished by April of 2007.


    At this web site you'll learn the sinister truth about other dangerous and defective GlaxoSmithKline drugs besides Paxil, including:

    Wellbutrin (a.k.a. Zyban), Serevent (a.k.a Advair), Imitrex, the LYMErix vaccine, the Trivax vaccine, Myodil, Relenza, Raxar and Lotronex. And we're researching others as well.

    You'll also learn how GlaxoSmithKline has used orphans and babies as young as three months old as virtual guinea pigs in potentially dangerous medical experiments involving HIV drugs, and vaccines. Think that movie The Constant Gardener was fantastical? Think again....

    Right about now you might be asking yourself "If this stuff is not true then why hasn't GlaxoSmithKline sued to shut this web site down? The answer is as simple as it is stunning: Because it is all true, and what GlaxoSmithKline does not want to do is risk drawing more attention to itself; unless, of course, it's through the company's glitzy TV ads, magazine slicks or glibly worded press releases. (GSK attorneys did make several covert attempts to shut down our Google AdWords campaign — but failed. There have been other "skirmishes" as well.)

    Think about this for a moment: here is one person who has managed to corner a corporate hyperpower with a public relations spear fashioned out of nothing more than a keyboard and computer. It's an incredible, and unprecedented, situation.

    But back to Paxil: While GlaxoSmithKline provides an abundance of information to the public and medical community about the alleged positive aspects of Paxil — through ads on television and in newspapers and magazines, promotional material provided to doctors, sponsorship of studies, medical meetings and seminars, substantial donations to mental health groups and organizations, government lobbying efforts, etc. — this independent site provides a nexus of information and resource links not readily available to the general public. Why isn’t the information presented on this website more well known, if known at all?  The answer is simple. It's because:

    GlaxoSmithKline wants it that way.

    If asked, GSK might tell you that — were the public told the truth about Paxil’s potential to cause oftentimes severe adverse reactions — patients who might have "benefited" from the drug would be scared away from taking it, "to their own detriment." (And to GSK's detriment as well, since the company was raking in several billion dollars a year in Paxil profits until this year (2005). Paxil isn't simply a "cash cow" for the company ... it's a whole herd in and of itself.

    However, it is up to you, the potential Paxil user — not GlaxoSmithKline — to decide what is right for you after full disclosure of Paxil's potential side effects have been made. (These warnings must be communicated in a clear and unambiguous manner. This means — insofar as Paxil is concerned — adding "a couple of extra teeth" to the "learned intermediary doctrine"; specifically, the Food and Drug Administration should implement a "risk management program" to ensure patients and physicians are fully informed of the real risks and alleged "benefits" of Paxil.)

    These protests, long overdue, follow in the grand tradition of American democracy. Society has a right, and a duty, to protect itself from companies that make a mockery of the public trust, and which operate in a manner antithetical to the public's health and well-being. (Perhaps some of you remember Ralph Nader's brilliant Unsafe At Any Speed campaign waged against the automobile industry in the 60's.)

    The Paxil Protest demonstrations will further expose the history of Paxil's development — a history in which GlaxoSmithKline knew even before Paxil was approved that its drug could induce suicidality, dependency and withdrawal. Furthermore, that GlaxoSmithKline (formerly SKB) conspired to hide these effects from the Food and Drug Administration in order to win approval for the drug. Why? So the company could seize upon and then dramatically expand into a burgeoning multi-billion dollar "SSRI" anti-depressant market.

    The Paxil Protest demonstrations will also focus the public's attention on additional hidden dangers of Paxil impacting women as a class, as well as the sub-population of women who are pregnant or who have just given birth to newborns.

    As a result of GlaxoSmithKline's hiding the truth from the public, approximately 5,000 U.S. citizens have filed suit against GSK for the oftentimes excruciatingly painful, prolonged, sometimes life-threatening withdrawal symptoms experienced when stopping the drug.

    Thousands more have sued GlaxoSmithKline in the U.K. on the same basis.

    Some of these lawsuits filed against GlaxoSmithKline are on behalf of individuals who started Paxil — only to discover they could not stop taking the drug (even with extraordinary medical intervention); as a consequence these persons have effectively been transformed into lifetime Paxil addicts.

    Additionally, hundreds of lawsuits filed against GlaxoSmithKline by families asserting Paxil was the proximate cause of death of their loved one via drug-induced suicide, (including children) are currently pending, or have been "resolved" by GlaxoSmithKline. Of these, the Donald Shell suicide/triple homicide is a standout. In this case, GlaxoSmithKline (in a classic example of corporate hubris) risked it all by squaring off with the families of the deceased in a backwoods Wyoming courtroom. GlaxoSmithKline lost the suit, and in spectacular fashion.

    "Do More, Feel Better, Live Longer" video

    (Windows Media Player or RealOne Player required to view)

    We welcome contributions from those interested in supporting our Paxil safety awareness campaign. Checks etc. can be mailed to: The Paxil Protest, P.O. Box 854, Chattanooga, TN 37401. You can also give by clicking on the "Visa/Mastercard" button below.

    Paxil is sold under many trade names throughout the world. For the latest news on the drug as Paxil , as Seroxat, as Aropax . Hot tip: Set yourself up with free Google News Alerts to have the latest on Paxil/Seroxat/Aropax delivered to you every day. (Each trade name should be set up as a separate news alert.) Paxil is also sold under the following trade names: Deroxat, Paroxet, Paxen, Paxetin, Paxtine, Paxxet, Tagonis, and XET.



    Please sign both and add your comments

    send us an email